NCT01424566View on ClinicalTrials.gov

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

June 29, 2012

Primary Completion Date

July 10, 2015

Study Completion Date

December 28, 2015

Conditions
PainAdvanced Cancer
Interventions
DRUG

Nabiximols

DRUG

Placebo (GA-0034)

Trial Locations (65)

404

Taichung

500

Changhua

1135

Budapest

2900

Komárom

3000

Vratsa

3002

East Melbourne

3050

Parkville

3800

Szikszó

4412

Nyíregyháza

6772

Deszk

9010

Varna

9700

Shumen

10002

Taipei

10099

Taipei

10126

Torino

11009

Cadiz

11213

Taipei

11490

Taipei

18014

Granada

20024

Garbagnate Milanese

28050

Madrid

29100

Piacenza

31096

Haifa

35578

Wetzlar

37129

Salamanca

41013

Seville

44534

Lünen

52621

Ramat Gan

60930

Ẕerifin

73657

Tainan City

76307

Šiauliai

78306

Ashkelon

84101

Beersheba

91120

Jerusalem

92288

Klaipėda

302017

Jaipur

410469

Oradea

411004

Pune

430241

Baia Mare

440055

Satu Mare

510077

Alba Iulia

550245

Sibiu

560034

Bangalore

620165

Focşani

720237

Suceava

810325

Brăila

07646

Stadtroda

08660

Vilnius

85-796

Bydgoszcz

41-250

Czeladź

80-208

Gdansk

44-101

Gliwice

57-300

Kłodzko

45-272

Opole

27-400

Ostrowiec Świętokrzyski

61-245

Poznan

02-781

Warsaw

02-793

Warsaw

87-800

Włocławek

010976

Bucharest

IP33 2QZ

Bury St Edmunds

EH4 2XR

Edinburgh

G12 0YN

Glasgow

M20 4BX

Manchester

NR4 7UY

Norwich

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

lead

Jazz Pharmaceuticals

INDUSTRY